Upstream Bio, Inc.

NASDAQ:UPB

Biotechnology

Healthcare
$2.08 +1.63%

+$0.10 today

Market cap
$114.01M
Beta
1.11
P/E (TTM)
-2.2
EPS (TTM)
-$2.89
52W Low $5.85High $33.68

Volume 1.24M

Average 0.66M

UPB Research & Development

Spending on developing new products, technologies, and improvements to existing offerings.

Upstream Bio, Inc.NASDAQ: UPB

Research & Development · Q1 FY2026 · quarter ended Mar 2026

Research & development grows, but more slowly than its trailing trend

Q1 FY2026 research & development of $36.57M rose 41.7% year over year, behind the +91.5% change in trailing-twelve-month research & development. Sequentially, it fell 9.0% from the prior quarter. Over 3 fiscal years it compounded at +94.3% a year.

Context

  • Research & development amounted to 4793.5% of revenue in FY2025, up 2136.7 pp from a year earlier.
  • Research & development increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from +41.7% toward the trailing-twelve-month pace of +91.5%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
$36.57M-9.0% QoQ
Last fiscal yearDec 2025
$136.81M+117.3% YoY
LTMMar 2026
$147.57M+91.5% YoY
Research & Development past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+41.7%——
1 year+117.3%——
3-year CAGR+94.3%——
5-year CAGR——
10-year CAGR——

Research & Development history

USD · from the income statement

Latest · FY2025
136.81M USD
Year-over-year change
+117.3%
3-year CAGR
+94.3%

Research & Development vs competitors

How UPB compares with its peers on the latest reported figures

  • Peers report in different currencies, so research & development is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +91.5% is the 2nd highest of 10, against a peer median of +7.0%.
  • Research & development amounts to 4442.3% of revenue for UPB, versus a peer median of 275.5%.
UPB Competitors
Research & Development for UPB and competitors
Company Period LTM YoY 3-year CAGR% of revenue
NTLAIntellia Therapeutics, Inc.LTM Mar 2026$361.17M USD-21.5%-2.5%546.5%
ZBIOZenas BioPharma, Inc.LTM Mar 2026$360.26M USD+137.9%+38.9%—
NVAXNovavax, Inc.LTM Mar 2026$345.36M USD-10.9%-35.2%57.9%
RLAYRelay Therapeutics, Inc.LTM Jun 2026$270.72M USD-4.1%+2.0%2615.7%
SYRESpyre Therapeutics, Inc.LTM Sep 2026$259.72M USD+46.3%+43.1%287.0%
SNDXSyndax Pharmaceuticals, Inc.LTM Mar 2026$255.99M USD+3.7%+29.7%117.9%
WVEWave Life Sciences Ltd.LTM Mar 2026$189.6M USD+13.6%+16.4%264.1%
UPBUpstream Bio, Inc.LTM Mar 2026$147.57M USD+91.5%+94.3%4442.3%
PHVSPharvaris N.V.LTM Sep 2026€132.22M EUR+7.0%+29.5%—
AMLXAmylyx Pharmaceuticals, Inc.LTM Sep 2026$100.83M USD+9.7%-1.1%—
Peer median (excluding UPB) —+7.0%+16.4%275.5%

Competitors are the stored peer set for UPB. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue1.21M2.38M2.37M2.85M
Cost of Revenue0000
Gross Profit1.21M2.38M2.37M2.85M
Gross Margin100.0%100.0%100.0%100.0%
Research & Development18.66M31.8M62.97M136.81M
Selling, General & Admin6.46M10.7M17.17M26.41M
Operating Expenses25.12M42.49M80.13M163.22M
Depreciation & Amortization7K60K89K188K
EBITDA(23.86M)(20.48M)(62.72M)(143.26M)
EBITDA Margin-1968.7%-860.4%-2646.3%-5019.4%
Operating Income(23.91M)(40.11M)(77.76M)(160.36M)
Operating Margin-1972.7%-1685.5%-3281.2%-5618.8%
Interest Income205K4.17M12.12M16.93M
Interest Expense0000
Other Income / Expenses41K19.58M14.96M16.92M
Income Before Tax(23.87M)(20.54M)(62.81M)(143.44M)
Pre-Tax Margin-1969.3%-862.9%-2650.0%-5026.0%
Income Tax Expense0000
Net Income(23.87M)(20.54M)(62.81M)(143.44M)
Net Margin-1969.3%-862.9%-2650.0%-5026.0%
EPS (Basic)(0.66)(1.05)(1.49)(2.66)
EPS (Diluted)(0.66)(1.05)(1.49)(2.66)
Weighted Avg Shares36.32M36.32M51.34M53.85M
Weighted Avg Shares (Diluted)36.32M36.32M51.34M53.85M

Upstream Bio, Inc.

NASDAQ:UPB

Intrinsic Alpha fair value

Locked

Current Price

$2.08

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.